Great talk by Otto Metzger from Dana-Farber at #SABCS23 on use of chemotherapy and CDK4/6 inhibitors in patients with early luminal-like #BreastCancer at higher risk of disease recurrence OncoAlert Dana-Farber’s Breast Oncology Center SABCS #bcsm

First ever triplet ph 3 in HR+ MBC: press release Tuesday, data to be presented this Friday #sabcs23! Roche announces positive Phase III results for inavolisib combination in people with advanced HR+, HER2- MBC with a PIK3CA mutation @oncoalert roche.com/media/releases…

Brilliant discussion by Laura Huppert, MD on HR+/HER2- eBC NACT + IO SABCS #eBC #Immunotherapy

#HER2CLIMB02 trial Important study in brain mets #tucatinib #HER2positive #aBC #SABCS23 SABCS

#MONARCH3 trial 1st line abemaciclib in HR+/HER2- aBC Clinically and numerically higher OS 66.8 vs 53.7 months #SABCS23 #abemaciclib SABCS

Prof Martine Piccart discussing on should we give or not #anthracyclines in #patients with #breastcancer #SABCS23 Institut Jules Bordet Instituut OncoAlert Guilherme Nader Marta ULB ComRecherche

🔜 @ PosterSession2, today 5PM #SABCS23 📍 COVID19-ABC study: impact of #COVID19 pandemic on advanced #bcsm clinical presentation Interested? 👉 Pass by PO2-10-11 SABCS to learn & discuss our main findings w/ my colleague & friend Guilherme Nader Marta 💫 OncoAlert #RWE

@BIGagainstBC HaDEA In PALLAS, no prognostic difference or differential benefit from palbociclib were observed according to HER2-low status 👉 Interestingly, a significant geographic heterogeneity in HER2-low prevalence was seen accross countries OncoAlert SABCS

Sub-analysis of #APHINITY trial #SABCS23 #HER2positive

#DB08 TRIAL in #SABCS23 DESTINY BREAST 08 trial #TDXd + #HT (Anastrozole or fulvestrant) in #HER2low advanced breast cancer SABCS

Comparing prognosis for #BRCA1 #BRCA2 and #nonBRCA breast cancer in #Portugal #SABCS23 BRCA associated with worse prognosis SABCS

Presented today at #SABCS23 and published in JAMA results of our study showing the feasibility and safety of #pregnancy after #BreastCancer in young #BRCA carriers OncoAlert SABCS AACR Università di Genova Ospedale San Martino Genova #bcsm Link here: jamanetwork.com/journals/jama/…

Dear Colleagues at #SABCS23 🇺🇸 Presenting the OncoAlert 🚨RoundUp for DAY3⃣ For a Deeper look REGISTER at OncoAlert360.com Discussing ✅GS02-13🤰by Matteo Lambertini, MD PhD 🇮🇹 JAMA ✅AVIATOR🛩️ ✅IDEA💡 ✅PREFERABLE -EFFECT ✅TROPION BREAST0⃣1⃣ ✅POSITIVE ➕ ✅NSABP B-51☢️

#NATALEE trial Adjuvant #ribociclib in HR+/HER2- #EBC Benefit across all subgroups! 📍#IDFS: ∆ 3.1% absolute benefit at 3y, producing a ⬇️ 25% risk reduction 📍#DDFS: ∆ 2.7% absolute benefit at 3y SABCS #SABCS23

#KATHERINE trial at #SABCS23 Adjuvant #TDM1 vs. Trastuzumab in #residual disease post NACT + anti-HER2 in #HER2 positive breast cancer > Final IDFS 📍∆ 13.7% absolute difference at 7y, benefit across all subgroups > 2nd OS IA 📍∆ 4.7% absolut difference at 7y

#INAVO120 primary analysis #inavolisib + #palbociclib + fulvestrant > Poor prognosis disease characteristics > #mPFS 15.0 vs. 7.3 months, HR 0.43! > #mOS NR vs. 31.1 months, HR 0.64! > #ORR 58.4% vs. 25.0% #SABCS23

Excited to share our latest letter to the editor in @AnnOncol: "Tumour Heterogeneity in Molecular Imaging for Breast Cancer" 🔬📄. Explore our insights on the challenges and advancements in molecular imaging. #Oncology #BreastCancer #MedicalResearch Thanks to all the team!

Just out in Cells MDPI: "CDK4/6 inhibitors on circulating cells in patients with metastatic breast cancer" 🧬📄. Read more: doi.org/10.3390/cells1… #BreastCancer #Oncology #CancerResearch #CDK46Inhibitors

Already 12m since my arrival at Institut Jules Bordet Instituut and no better way to celebrate the ESMO - Eur. Oncology fellowship, which will allow me to continue my 🇧🇪journey! Thank you for this amazing experience Lucia Del Mastro, Matteo Lambertini, MD PhD Evandro de Azambuja, MD, PhD Elisa Agostinetto Soraia Lobo-Martins Chiara Dauccia